Related medicinesGlucagonDasiglucagon
Where it comes from
- Made in
- Alpha cells of the pancreatic islets
- Sent out by
- Falling blood glucose, amino acids after a protein meal, adrenaline and exercise; insulin and somatostatin hold it back
- Acts on
- Liver
- Fat tissue
- Heart
What it does
In medicine
- Glucagon is the rescue injection for severe hypoglycaemia; a nasal powder (2019) and ready-to-use pens of dasiglucagon (2021) followed 2
- The glucagon stimulation test probes growth hormone and cortisol reserve
- Given to relax the gut during imaging and endoscopy
Beyond the body’s own use
- Glucagon receptor activity is built into the dual and triple agonists survodutide, mazdutide and retatrutide: the glucagon part raises energy expenditure, the GLP-1 part curbs appetite. Mazdutide took off 16.7% of body weight against 1.5% on placebo in a 461-person Chinese phase 3 trial 4 and is approved in China for weight management; the others have reported phase 3 results in obesity and are not approved
- Blocking the receptor instead was tried and largely abandoned: in phase 2 trials in type 2 diabetes, glucagon receptor antagonists lowered glucose but raised liver fat, liver enzymes and LDL cholesterol 3
- Pumps that give glucagon alongside insulin, the bihormonal closed loop, are in trials in type 1 diabetes and are not approved
Sources
- Müller et al., The new biology and pharmacology of glucagon, Physiological Reviews 2017
- Dasiglucagon (Zegalogue), FDA application NDA 214231
- Kazda et al., The glucagon receptor antagonist LY2409021 in type 2 diabetes, Diabetes Care 2016
- Gao et al., Mazdutide for weight reduction in Chinese adults with obesity (GLORY-2), JAMA 2026
This card describes what a medicine is for and what the evidence says; it recommends nothing. Talk to your clinician about anything you read here.